Crizotinib

Crizotinib is a small-molecule tyrosine kinase inhibitor targeting ALK (anaplastic lymphoma kinase), ROS1, and MET receptors. It is primarily used in the treatment of ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). Mediocon Inc supplies pharmaceutical-grade Crizotinib meeting USP, BP, EP, and IP standards for bulk pharma manufacturing.

Key Features

• Analgesic, antipyretic & anti-inflammatory
• USP/BP/IP compliant quality
• Widely used in cardiovascular therapy
• Suitable for tablet and effervescent formulations

Applications

• Non-small cell lung cancer (NSCLC)
• ALK-positive & ROS1-positive tumors
• MET amplification or exon 14-mutated NSCLC
• Clinical research oncology formulations

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings